‘Our tech stocks have done well’: We’re in our mid-50s and 85% invested in stocks. Is this too aggressive for the next 10 years?

• We're lightening up on a rallying stock that's grown too big in our portfolio

  The sale also comes as our trusted momentum indicator moved further into overbought territory.
  
  CNBC - Jan. 28

• Our health-care stocks keep on climbing as DeepSeek fears pressure most of our AI names

  Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
  
  CNBC - Jan. 27

• Here's my list of catalysts that could drive each of our 33 stocks higher in 2025

  During the Investing Club's Monthly Meeting, Jim Cramer ran through events, trends and more that could propel each of our stocks higher this year.
  
  CNBC - Jan. 23

• Our 5 top-performing portfolio stocks since December's Monthly Meeting are tech free

  The S&P 500 has jumped 3.7% since the December Monthly Meeting to Wednesday's close.
  
  CNBC - Jan. 23

• Space stocks skyrocket after Trump vows to ‘pursue our manifest destiny into the stars’

  Trump thrust a spotlight on the future of American space exploration during his inauguration speech Monday.
  
  MarketWatch - Jan. 21

• From tariffs to energy to AI: What Trump's busy return to the White House means for our stocks

  The batch of executive orders and commentary have implications for Coterra Energy, Meta Platforms and more Club stocks.
  
  CNBC - Jan. 21

• Wall Street names 13 of our stocks 'top picks' for 2025 — here's the list and our takes

  These are names analysts say can not only weather any headwinds but will thrive in the new year.
  
  CNBC - Jan. 9

• We're trimming our stake in a beaten-up stock that has taken off in 2025

  The stock is our top-performing holding in the new year.
  
  CNBC - Jan. 6

More from MarketWatch

• My friend, 62, was given 6 months to live, but he may only have weeks. How does he prevent his second wife from inheriting everything?

  “Without his disability checks, his second wife might end up having to sell the house.”
  
  MarketWatch - 44m

• New York Times’ stock falls as analysts question its promotional spending

  Media company’s fourth-quarter subscribers reach 11.43 million, while it hikes its dividend by 38% and sets stock buyback.
  
  MarketWatch - 45m

• This is how much Mattel’s $600 million buyback could boost earnings

  Mattel is ramping up its share repurchase efforts. Analyst firm UBS expects an earnings boost from the toy maker.
  
  MarketWatch - 51m

• Oil prices drop on rising U.S. inventories and fears tariffs will dent Chinese demand

  Oil futures fell Wednesday, poised to mark their lowest settlement of the year so far, after official U.S. data showed a weekly climb of nearly 9 million barrels in U.S. crude inventories and as ...
  
  MarketWatch - 52m

• Why Trump’s sovereign-wealth fund won’t MAGA

  I’ll take a hard pass on this idea
  
  MarketWatch - 54m

More in Business

• Could Trump's tariffs replace the income tax? Here's what policy experts say

  During the campaign, President Donald Trump floated an "all tariff policy" to replace the federal income tax. Here's what experts say about the idea.
  
  CNBC - 8m

• Could Trump's tariffs replace the income tax? Here's what policy experts say

  During the campaign, President Donald Trump floated an "all tariff policy" to replace the federal income tax. Here's what experts say about the idea.
  
  CNBC - 8m

• What the 'mother of all trade wars' can teach us about U.S. tariffs, according to economists

  Here's how current events are mirroring a key point in U.S. history that led to a trade war and exacerbated the Great Depression, according to economists.
  
  CNBC - 17m

• National Women's Soccer League agrees to $5 million settlement over past mistreatment of players

  The NWSL and three attorneys general have agreed to a settlement over the league's past mistreatment of players.
  
  CNBC - 19m
• 

  Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

  The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
  
  The New York Times - 25m